-
公开(公告)号：US11236106B2
公开(公告)日：2022-02-01
申请号：US17243360
申请日：2021-04-28
发明人： Kenji Yoshikawa , Noriyasu Haginoya , Tomoaki Hamada , Ryutaro Kanada , Jun Watanabe , Yoshiko Kagoshima , Eri Tokumaru , Kenji Murata , Takayuki Baba , Mayumi Kitagawa , Akiko Kurimoto , Masashi Numata , Machiko Shiroishi , Taeko Shinozaki
IPC分类号： C07D495/04 , A61P35/02 , A61K45/06
摘要： The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.
-
公开(公告)号：US20210269454A1
公开(公告)日：2021-09-02
申请号：US17243360
申请日：2021-04-28
发明人： Kenji Yoshikawa , Noriyasu Haginoya , Tomoaki Hamada , Ryutaro Kanada , Jun Watanabe , Yoshiko Kagoshima , Eri Tokumaru , Kenji Murata , Takayuki Baba , Mayumi Kitagawa , Akiko Kurimoto , Masashi Numata , Machiko Shiroishi , Taeko Shinozaki
IPC分类号： C07D495/04 , A61K45/06 , A61P35/02
摘要： The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.
-
公开(公告)号：US20230030720A1
公开(公告)日：2023-02-02
申请号：US17289710
申请日：2019-12-05
发明人： Kenji Yoshikawa , Noriyasu Haginoya , Tomoaki Hamada , Ryutaro Kanada , Jun Watanabe , Yoshiko Kagoshima , Eri Tokumaru , Kenji Murata , Takayuki Baba , Mayumi Kitagawa , Akiko Kurimoto , Masashi Numata , Machiko Shiroishi , Taeko Shinozaki
IPC分类号： C07D495/04 , C07D519/00 , C07D403/12 , C07D403/14 , A61K45/06
摘要： The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.
-
公开(公告)号：US09156817B2
公开(公告)日：2015-10-13
申请号：US14337586
申请日：2014-07-22
IPC分类号： C07D401/12 , C07D239/30 , C07D239/36 , C07D239/42 , C07D239/47 , C07D239/48 , C07D241/20 , C07D401/14 , C07D405/14
CPC分类号： C07D401/12 , C07D239/30 , C07D239/36 , C07D239/42 , C07D239/47 , C07D239/48 , C07D241/20 , C07D401/14 , C07D405/14
摘要： Compounds of Formula (I) promote axonal outgrowth angiogenesis and can therefore be used to reduce central nerve injuries such as head injury and spinal cord injury, cerebral infarction, ischemic heart diseases, peripheral arterial occlusive diseases, or after-effects of these diseases. in which Nx group is preferably a 6-membered aromatic ring containing two nitrogen atoms; R0, R1 and R2 are each independently a hydrogen atom, an alkyl group, or an amino group; E is an oxygen atom or an —NR8 group (wherein R8 is an alkyl group or the like); n is an integer of 0 to 5; X and Y are each a connecting bond, a cycloalkyl group, or —CO—; and Q is a hydrogen atom or a phenyl group.
-
5.发明授权公开(公告)号：US09139559B2
公开(公告)日：2015-09-22
申请号：US14173327
申请日：2014-02-05
IPC分类号： C07D401/12 , C07D239/30 , C07D239/36 , C07D239/42 , C07D239/47 , C07D239/48 , C07D241/20 , C07D401/14 , C07D405/14
CPC分类号： C07D401/12 , C07D239/30 , C07D239/36 , C07D239/42 , C07D239/47 , C07D239/48 , C07D241/20 , C07D401/14 , C07D405/14
摘要： Compounds of Formula (I) promote axonal outgrowth angiogenesis and can therefore be used to reduce central nerve injuries such as head injury and spinal cord injury, cerebral infarction, ischemic heart diseases, peripheral arterial occlusive diseases, or after-effects of these diseases. in which Nx group is preferably a 6-membered aromatic ring containing two nitrogen atoms; R0, R1 and R2 are each independently a hydrogen atom, an alkyl group, or an amino group; E is an oxygen atom or an —NR8 group (wherein R8 is an alkyl group or the like); n is an integer of 0 to 5; X and Y are each a connecting bond, a cycloalkyl group, or —CO—; and Q is a hydrogen atom or a phenyl group.
摘要翻译： 式（I）的化合物促进轴突生长的血管生成，因此可用于减少中枢神经损伤，例如头部损伤和脊髓损伤，脑梗死，缺血性心脏病，外周动脉闭塞性疾病或这些疾病的后遗症。 其中Nx基团优选为含有两个氮原子的6元芳族环; R 0，R 1和R 2各自独立地为氢原子，烷基或氨基; E是氧原子或-NR8基（其中R8是烷基等）; n为0〜5的整数， X和Y各自为连接键，环烷基或-CO-; Q为氢原子或苯基。
-
公开(公告)号：US20230074669A1
公开(公告)日：2023-03-09
申请号：US17535369
申请日：2021-11-24
发明人： Kenji Yoshikawa , Noriyasu Haginoya , Tomoaki Hamada , Ryutaro Kanada , Jun Watanabe , Yoshiko Kagoshima , Eri Tokumaru , Kenji Murata , Takayuki Baba , Mayumi Kitagawa , Akiko Kurimoto , Masashi Numata , Machiko Shiroishi , Taeko Shinozaki
IPC分类号： C07D495/04 , A61P35/02 , A61K45/06
摘要： The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.024 秒)
